All patients
invasive ventilation non invasive oxygen
miscellaneous in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results VERU-111, 2022 0.30 [0.14; 0.64]
0.30 [0.14 ; 0.64 ] VERU-111, 2022 1 0% 150 NA not evaluable death D28detailed results Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gunst JD, 2021 0.99 [0.29; 3.42]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
0.71 [0.35 ; 1.45 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, RECOVERY (Aspirin), 2022 3 64% 15,285 moderate not evaluable death or transfer to ICUdetailed results Gunst JD, 2021 0.55 [0.26; 1.17]
0.55 [0.26 ; 1.17 ] Gunst JD, 2021 1 0% 205 NA not evaluable deathsdetailed results Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gunst JD, 2021 0.70 [0.20; 2.49]
Nouri-Vaskeh, 2021 0.35 [0.06; 1.91]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
0.62 [0.32 ; 1.19 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Nouri-Vaskeh, 2021, RECOVERY (Aspirin), 2022 4 58% 15,368 moderate not evaluable deaths (time to event analysis only)detailed results Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gunst JD, 2021 0.70 [0.20; 2.49]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
0.66 [0.32 ; 1.36 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, RECOVERY (Aspirin), 2022 3 66% 15,288 moderate not evaluable clinical improvementdetailed results Gunst JD, 2021 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] Gunst JD, 2021 1 0% 208 NA not evaluable clinical improvement (time to event analysis only)detailed results Gunst JD, 2021 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] Gunst JD, 2021 1 0% 208 NA not evaluable death or ventilationdetailed results Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
0.46 [0.22 ; 0.96 ] Fragoso-Saavedra (PISCO), 2020 1 0% 188 NA not evaluable hospital dischargedetailed results Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10]
1.06 [1.02 ; 1.10 ] Fragoso-Saavedra (PISCO), 2020, RECOVERY (Aspirin), 2022 2 0% 15,080 moderate not evaluable mechanical ventilationdetailed results Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Gunst JD, 2021 2.27 [0.62; 8.26]
1.32 [0.50 ; 3.45 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021 2 21% 393 moderate not evaluable mechanical ventilation (time to event analysis only)detailed results Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
Gunst JD, 2021 0.69 [0.14; 3.42]
0.77 [0.31 ; 1.90 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021 2 0% 396 moderate not evaluable ICU admissiondetailed results Gunst JD, 2021 0.80 [0.34; 1.90]
0.80 [0.34 ; 1.90 ] Gunst JD, 2021 1 0% 205 NA not evaluable recoverydetailed results Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
Gunst JD, 2021 1.18 [0.87; 1.61]
1.03 [0.58 ; 1.84 ] Crippa (CANDIDATE), 2021, Gunst JD, 2021 2 26% 299 moderate not evaluable serious adverse eventsdetailed results Gunst JD, 2021 1.84 [0.79; 4.30]
1.84 [0.79 ; 4.30 ] Gunst JD, 2021 1 0% 205 NA not evaluable adverse eventsdetailed results Gunst JD, 2021 0.80 [0.43; 1.51]
0.80 [0.43 ; 1.51 ] Gunst JD, 2021 1 0% 205 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:56 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924
- roots T: 290